Itraconazole vs amphotericin B: in vitro comparative evaluation of the minimal inhibitory concentration (MIC) against clinically isolated yeasts

G. Lombardi, G. Gramegna, C. Cavanna, G. Poma, E. Marangoni, G. Michelone

Research output: Contribution to journalArticlepeer-review

Abstract

Itraconazole is a triazole compound which, following several clinical trials, has begun to be used for therapy of mycotic infections. This new drug, with a broad-spectrum antifungal activity, can be orally administered. The Authors studied the in vitro susceptibility to amphotericin B and itraconazole of the following clinical isolates of pathogenic yeasts: 100 Candida albicans, 20 C. tropicalis, 20 C. parapsilosis, 8 C. guilliermondii, 6 C. pseudotropicalis, 24 Torulopsis glabrata and 16 Cryptococcus neoformans. Serial two-fold dilutions, from 100 μg/ml to 0.04 μg/ml, of each drug were prepared in Yeast Nitrogen Base + Glucose 5%, after dissolving the itraconazole in dimethylsulfoxide (DMSO) and amphotericin B in 5% glucose solution. Amphotericin B (MIC90: 3.12 μg/ml) was found to have an average in vitro MIC six-fold lower than itraconazole (MIC90: 25 μg/ml). Thus, even though itraconazole is active, amphotericin B remains one of the most effective of the antifungal drugs.

Original languageEnglish
Pages (from-to)31-34
Number of pages4
JournalMycopathologia
Volume106
Issue number1
DOIs
Publication statusPublished - Apr 1989

Keywords

  • amphotericin B
  • itraconazole
  • susceptibility testing
  • yeast infections

ASJC Scopus subject areas

  • Plant Science
  • Agricultural and Biological Sciences (miscellaneous)

Fingerprint Dive into the research topics of 'Itraconazole vs amphotericin B: in vitro comparative evaluation of the minimal inhibitory concentration (MIC) against clinically isolated yeasts'. Together they form a unique fingerprint.

Cite this